登录
| 企业文档数据库
  • 首页
  • 医学材料
    • 指南共识
    • 循证证据
    • 推荐观点
    • 临床项目
  • 产品信息/适应症
    • 宁泌泰胶囊
    • 夏枯草口服液
    • 苦参凝胶
    • 坤泰胶囊
    • 注射用西维来司他钠
    • 佐愈
    • 蒂诺安
    • 匹瑞
    • 卫达甘
  • 市场材料
    • 应用场景
    • 推荐观点
    • 市场活动
    • 绿卡
    • 事业部医学支持
    • 案例中心
  • 科室及医护人员
    • 内科
    • 外科
    • 重点科室
    • 医护群体
登录
  1. 首页
  2. 医学材料
  3. 循证证据
  4. 产品信息/适应症
  5. 汇伦医药
  6. 注射用西维来司他钠
  7. 科室及医护人员
  8. 内科
  9. 外科
  10. 重点科室
  11. 心内科
  12. ICU
  13. 急诊
  14. 心外科
  15. 心外ICU
  16. 正文

The effects of a neutrophil elastase inhibitor on the postoperative respiratory failure of acute aortic dissection

收藏
文章来源:
摘要:Background:Postoperative respiratory failure is often encountered in patients suffering from acute aortic dissection (AAD) and is believed to be influenced by release of neutrophil elastase after cardiopulmonary bypass. Sivelestat is a specific neutrophil elastase inhibitor, and this study aims to evaluate the effects of sivelestat on postoperative respiratory failure due to AAD. Methods and results:Patients who were operated for AAD from January 2000 to April 2005 and who had less than 300 mmHg initial postoperative PaO (2)/FiO (2) were investigated retrospectively and divided into two groups. Group 1 (n = 9) received intravenous administration of sivelestat immediately after the operation, while Group II (n = 9) received no sivelestat. There were no significant differences between Group I and II with respect to patients' characteristics or background (age, body weight, operating time, cardiopulmonary bypass time, amount of bleeding, preoperative WBC number and initial PaO (2)/FiO (2)). Though patients in Group I showed a subtle improvement in certain parameters such as PaO (2)/FiO (2), A-aDO (2) and respiratory index (RI) over a 3-day observation period compared to those of Group II, there were no significant differences. Neither postoperative mechanical ventilation time nor ICU stay differed between Group I and II. However, Group I showed a significantly greater improvement in the ratio of RI to initial RI on the 3POD compared to that of Group II (61.6 +/- 44.2 % vs. 111.9 +/- 40.9 %, P = 0.02). Conclusion:Inhibiting the activity of the neutrophil elastase may attenuate the postoperative respiratory complications of patients with AAD.
标签: 心外CPB术后 产品信息/适应症 汇伦医药 西维来司他钠 ICU 外科 急诊
查看数:139
发布时间:2024-09-04 邹文成
公开


文档附件清单
  • 附件1: 下载附件
评论
0
      医学材料热门文章
      • 1. 急性呼吸窘迫综合征抗炎治疗中中性粒细胞弹性蛋白酶抑制剂急诊应用专家共识
      • 2. A New Global Definition of Acute Respiratory Distress Syndrome
      • 3. 中国创伤性脊髓损伤流行病学和疾病经济负担的系统评价
      • 4. 西维来司他钠联合俯卧位通气在急性肺损伤/急性呼吸窘迫综合征中的疗效评价
      • 5. 西维来司他钠治疗ARDS患者的效果及其应用价值
      • 6. The Protective Effects of Sivelestat Sodium on the Basis of Corticosteroid Therapy in Patients With Moderate-to-Severe Acute Respiratory Distress Syndrome
      • 7. 西维来司他钠对颅脑损伤合并ARDS患者的一项多中心、前瞻性、双盲、随机对照试验
      • 8. 西维来司他钠在中国重症肺炎患者中的群体药代动力学
      • 9. 西维来司他钠在ICU不同疾病合并ARDS患者中的应用效果
      • 10. 有创-无创序贯通气疗法联合美罗培南、西维来司他钠治疗急性呼吸窘迫综合征的效果及对炎性因子水平的影响
      热门文章
      • 1. 急性呼吸窘迫综合征抗炎治疗中中性粒细胞弹性蛋白酶抑制剂急诊应用专家共识
      • 2. A New Global Definition of Acute Respiratory Distress Syndrome
      • 3. 中国创伤性脊髓损伤流行病学和疾病经济负担的系统评价
      • 4. 西维来司他钠联合俯卧位通气在急性肺损伤/急性呼吸窘迫综合征中的疗效评价
      • 5. 西维来司他钠治疗ARDS患者的效果及其应用价值
      • 6. 希为纳EDA
      • 7. The Protective Effects of Sivelestat Sodium on the Basis of Corticosteroid Therapy in Patients With Moderate-to-Severe Acute Respiratory Distress Syndrome
      • 8. 希为纳围术期病例库(心外/神外/胸外/肝胆外)
      • 9. 西维来司他钠对颅脑损伤合并ARDS患者的一项多中心、前瞻性、双盲、随机对照试验
      • 10. 西维来司他钠在中国重症肺炎患者中的群体药代动力学

      版权所有 © 上海汇伦医药股份有限公司 沪ICP备17025706号-2